References

1. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA. 1965;191:541-546.

2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science. 1989;224:359-362.

3. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology. 2001;120:1828-1853.

4. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Eng J Med. 1999;341:1256-1263.

5. Duverlie G, Khorsi H, Castelain S, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol. 1998;79:1373-1381.

6. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27: 1670-1677.

7. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325-329.

8. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology. 1997;26:786-791.

9. McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology. 1992;15:757-766.

10. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 1994;68:8102-8110.

11. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588-591.

12. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat. 1997;4: 1-8.

13. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol. 2000;38:2897-2901.

14. Pawlotsky JM, Prescott L, Simmonds P, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol. 1997;35:1734-1739.

15. Zaaijer HL, ter Borg F, Cuypers TM, Hermus MCAH, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol. 1994;32:2088-2091.

16. Gerken G, Gomes J, Lampertico P, et al. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods. 1998;74:155-165.

17. Noborg U, Gusdal A, Pisa EK, Hedrum A, Lindh M. Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test. J Clin Microbiol. 1999;37:2793-2797.

18. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol. 2000;38:702-707.

19. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 1993;105:1833-1838.

20. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630-1635.

21. Pawlotsky JM, Bastie A, Hezode C, et al. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods. 2000;85:11-21.

22. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A; WHOCSG. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 2001;80:63-71.

23. Krajden M, Comanor L, Rifkin O, Grigoriew A, Minor JM, Kapke GF. Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay. J Clin Microbiol. 1998;36: 382-386.

24. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA. 1991;88: 2451-2455.

25. Okamoto H, Kurai K, Okada S, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology. 1992;188: 331-341.

26. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci USA. 1993;90:8234-8238.

27. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA. 1994;91: 8239-8243.

28. Simmonds P, Holmes EC, Cha T-A, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phyloge-netic analysis of the NS-5 region. J Gen Virol. 1993;74:2391-2399.

29. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995;15: 41-63.

30. Tokita H, Okamoto H, Iizuka H, et al. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol. 1996;77:293-301.

31. Tokita H, Okamoto H, Tsuda F, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci U S A. 1994;91:11022-11026.

32. Lau JYN, Davis GL, Prescott LE, et al. and the Hepatitis Intervential Therapy Group. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med. 1996;124:868-876.

33. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994;19:13-18.

34. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology. 1997;25:211-215.

35. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349: 825-832.

36. National Institutes of Health. Management of hepatitis C. NIH Consens Statement. 2002;19:1-46.

37. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998; 47:1-39.

38. EASL International Consensus Conference on Hepatitic C. Consensus statement. J Hepatol. 1999;30:956-961.

39. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050-2068.

40. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Morb Mortal Wkly Rep.. 2003;52:1-15.

41. Fanning L, Kenny-Walsh E, Levis J, et al. Natural fluctuations of hepatitis C viral load in the homogeneous patient population: a prospective study. Hepatology. 2000;31:225-229.

42. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med. 2002; 347:975-982.

43. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol. 2002;37:500-506.

44. Poynard T, McHutchison JG, Goodman ZD, Ling M-H, Albrecht J for the ALGOVIRC Project Group. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C. Hepatology. 2000;31: 211-218.

45. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Eng J Med. 1996;334:1685-1690.

46. Legler TJ, Riggert J, Simson G, et al. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion. 2000;40:1192-1197.

47. Kolk DP, Dockter J, Linnen J, et al. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus presero-conversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol. 2002;40:1761-1766.

48. Ansaldi F, Torre F, Bruzzone BM, Picciotto A, Crovari P, Icardi G. Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. J Med Virol. 2001;63:17-21.

49. Icardi G, Ansaldi F, Bruzzone BM, et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol. 2001;39:3110-3114.

50. Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002;36:211-218.

51. McHutchison JG, Gordon S, Schiff ER, et al. for the Hepatitis Inter-ventional Therapy Group. Interferon alpha-2b alone or in combination of ribavirin as initial treatment for chronic hepatitis C. N Eng J Med. 1998;339:1485-1499.

52. Poynard T, Marcellin P, Lee SS, et al. for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.

53. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol. 1996;91:1516-1522.

54. Hohne M, Schreier E, Roggendorf M. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch Virol. 1994;137:25-34.

55. Power JP, Lawlor E, Davidson F, Holmes EC, Yap PL, Simmonds P. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet. 1995;345:1211-1213.

56. Bronowicki JP, Venard V, Botte C, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Eng J Med. 1997;337:237-240.

57. Aizaki H, Saito A, Kusakawa I, et al. Mother-to-child transmission of a hepatitis C virus variant with an insertional mutation in its hypervariable region. J Hepatol. 1996;25:608-613.

58. Chayama K, Kobayashi M, Tsubota A, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol. 1995;22: 431-439.

59. Healey CJ, Smith DB, Walker JL, et al. Acute hepatitis C infection after sexual exposure. Gut. 1995;36:148-150.

60. Weiner AJ, Thaler MM, Crawford K, et al. A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J Virol. 1993;67:4365-4368.

61. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstruc-tural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Eng J Med. 1996;334:77-81.

62. Watanabe H, Enomoto N, Nagayama K, et al. Number and position of mutations in the interferon (IFN) sensitivity—determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus 1b infection. J Infect Dis. 2001;183: 1195-1203.

63. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol. 1997;53:118-126.

64. Sarrazin C, Berg T, Lee JH, et al. Improved correlation between multiple mutations within the NS5A region and virological response in

European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol. 1999;30:1004-1013.

65. Lee SC, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol. 2000;38:4171-4179.

66. Nolte FS, Fried MW, Shiffman ML, et al. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol. 2001;39:4005-4012.

67. Comanor L, Anderson F, Ghany M, et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol. 2001;96:2968-2972.

68. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology. 2000;32: 818-823.

69. Sarrazin C, Hendricks DA,Sedarati F, Zeuzem S. Assessment,by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol. 2001;39:2850-2855.

70. Krajden M, Ziermann R, Khan A, et al. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol. 2002;40:2903-2907.

71. Jackson JB, Smith K, Knott C, et al. Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Micro-biol. 2002;40:2387-2391.

72. Beld M, Sentjens R, Rebers S, et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J Clin Microbiol. 2002;40:788-793.

73. Germer JJ, Heimgartner PJ, Ilstrup DM, Harmsen WS, Jenkins GD, Patel R. Comparative evaluation of the Versant HCV RNA 3.0, Quan-tiplex HCV RNA 2.0, and COBAS Amplicor HCV Monitor version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol. 2002;40:495-500.

74. Kleiber J, Walter T, Haberhausen G, Tsang S, Babiel R, Rosenstraus M. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. J Mol Diagn. 2000;2:158-166.

75. Barbeau JM, Goforth J, Caliendo AM, Nolte F. Performance characteristics of a quantitative, TaqMan hepatitis C virus RNA analyte specific reagent. J Clin Microbiol. 2004:in press.

76. Caliendo AM, Valsamakis A, Zhou Y, et al. Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol. 2006;44:1726-1732.

77. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyp-ing. J Clin Microbiol. 1996;34:2259-2266.

78. Andonov A, Chaudhary RK. Subtyping of hepatitis C virus isolates by a line probe assay using hybridization. J Clin Microbiol. 1995;33: 254-256.

79. Viazov S, Zibert A, Ramakrishnan K,et al. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods. 1994;48: 81-91.

80. Smith DB, McAllister J, Casino C, Simmonds P. Virus "quasispecies": making a mountain out of a molehill? J Gen Virol. 1997;78:1511-1519.

81. Ross RS,Viazov SO, Holtzer CD, et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol. 2000;38:3581-3584.

82. Halfon P, Trimoulet P, Bourliere M, et al. Hepatitis C virus genotyp-ing based on 5' noncoding sequency analysis (Trugene). J Clin Microbiol. 2001;39:1771-1773.

83. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol. 2002;76:4034-4043.

84. Hu YW, Balaskas E, Kessler G, et al. Primer specific and mispair extension analysis (PSMEA) as a simple approach to fast genotyp-ing. Nucleic Acids Res. 1998;26:5013-5015.

85. Krekulova L, Rehak V, Wakil AE, Harris E, Riley LW. Nested restriction site-specific PCR to detect and type hepatitis C virus (HCV): a rapid method to distinguish HCV subtype 1b from other genotypes. J Clin Microbiol. 2001;39:1774-1780.

86. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol. 1995;76:1197-1204.

87. White PA, Zhai X, Carter I, Zhao Y, Rawlinson WD. Simplified hepatitis C virus genotyping by heteroduplex mobility analysis. J Clin Microbiol. 2000;38:477-482.

88. Bullock GC, Bruns DE, Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem. 2002;48:2147-2154.

89. Schroter M, Zollner B, Schafer P, et al. Genotyping of hepatitis C virus types 1,2,3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes. J Clin Microbiol. 2002;40:2046-2050.

90. Dixit V, Quan S, Martin P, et al. Evaluation of a novel serotyping system for hepatitis C virus: strong correlation with standard geno-typing methodologies. J Clin Microbiol. 1995;33:2978-2983.

91. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Eng J Med. 1992;327:1490-1495.

92. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coin-fected with HIV. AIDS. 1995;9:1131-1136.

93. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10.

94. Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang. 1999;76:149-158.

95. Stelzl E, Kormann-Klement A, Haas J, et al. Evaluation of an automated sample preparation protocol for quantitative detection of hepatitis C virus RNA. J Clin Microbiol. 2002;40:1447-1450.

96. Nolte F, Green AM, Fiebelkorn KR, et al. Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 5' noncoding region. J Clin Microbiol. 2003;41:1558-1564.

0 0

Post a comment